RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2024 ended September 30, 2024, after the market closes on Wednesday, November 6, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Shares of Amphastar Pharmaceuticals Inc (AMPH, Financial) fell 3.54% in mid-day trading on Oct 2. The stock reached an intraday low of $46.58, before recovering slightly to $46.64, down from its previous close of $48.35.
Amphastar Pharmaceuticals shows promising growth potential with its diverse product offerings, including the nasally administered glucagon treatment BAQSIMI and the over-the-counter inhalant Primatene MIST. The company's solid balance sheet, with a current ratio of 3.52 and manageable debt levels, provides flexibility to navigate market changes. Risks include reliance on single-source supplies,...
RANCHO CUCAMONGA, CA / ACCESSWIRE / August 28, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 am EST. For access, visit Amphastar's Pharmaceuticals website at http...
The three-week market selloff sparked by recession fears was led by plunging tech, cyclical, industrial, and energy stocks. High-quality stocks clobbered in the past 30 days, and others beaten down in the past year offer potential buying opportunities. We identified 6 stocks down by double digits within the last year with Buy or Strong Buy Quant Ratings, high forward growth metrics, and attract...
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer Tony Marrs - Executive Vice President, Regulatory Affairs and Clinical Operations Conference Call Participants Ekaterina Knyazkova - JPMorgan David Amsellem - Piper...
Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 7, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2024. Second Quarter Highlights Net revenues of $182.4 million for the second quarter GAAP net income of $37.9 million, or $0.73...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.